As of the latest Form 4 filed Jun 29, 2026.
What CG Oncology, Inc. Common stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 21 most recent filings for CGON.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-29 | 2026-06-25 | Liu Brian Guan-Chyun Director | PPurchase | +371K | $66.87 | $24.8M | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-24 | POST LEONARD E Director | SSale | −5.00K | $70.00 | $350K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-24 | POST LEONARD E, Director | MExercise | +5.00K | $0.60 | $3.00K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-22 | POST LEONARD E Director | SSale | −5.00K | $65.00 | $325K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-22 | POST LEONARD E, Director | MExercise | +5.00K | $0.60 | $3.00K | Yes (planned) | Form 4 ↗ |
| 2026-06-16 | 2026-06-15 | Mulay James Director | SSale | −1.31K | $60.12 | $78.8K | Yes (planned) | Form 4 ↗ |
| 2026-06-16 | 2026-06-15 | Mulay James, Director | MExercise | +1.31K | $12.59 | $16.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-16 | 2026-06-15 | Mulay James, Director | SSale | −654.00 | $60.12 | $39.3K | Yes (planned) | Form 4 ↗ |
| 2026-06-16 | 2026-06-15 | Mulay James, Director | MExercise | +654.00 | $3.72 | $2.43K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | POST LEONARD E Director | SSale | −1.00K | $54.50 | $54.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | POST LEONARD E, Director | MExercise | +1.00K | $0.60 | $600.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-20 | 2026-04-17 | Mulay James Director | SSale | −15.6K | $73.01 | $1.14M | Yes (planned) | Form 4 ↗ |
| 2026-04-20 | 2026-04-17 | Mulay James, Director | MExercise | +15.6K | $36.63 | $571K | Yes (planned) | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Mulay James Director | SSale | −1.31K | $63.50 | $83.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Mulay James, Director | MExercise | +1.31K | $12.59 | $16.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Mulay James, Director | SSale | −654.00 | $63.50 | $41.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Mulay James, Director | MExercise | +654.00 | $3.72 | $2.43K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Kuan Arthur Chief Executive Officer | FTax | −1.85K | $60.15 | $111K | No | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Kuan Arthur, Chief Executive Officer | MExercise | +64.6K | $1.72 | $111K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Kuan Arthur Chief Executive Officer | FTax | −2.87K | $61.61 | $177K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Kuan Arthur, Chief Executive Officer | MExercise | +103K | $1.72 | $177K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also CGON’s full analysis or the market-wide insider trading feed. The tabs above jump to CGON’s other SEC data.
Source: SEC Form 4 filings for CGON, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.